{"id":"NCT00680186","sponsor":"Boehringer Ingelheim","briefTitle":"Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)","officialTitle":"A Phase III, Randomised, Double Blind, Parallel-group Study of the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism, Following Initial Treatment (5-10 Days) With a Parenteral Anticoagulant Approved for This Indication","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2011-05","completion":null,"firstPosted":"2008-05-20","resultsPosted":"2012-06-14","lastUpdate":"2014-05-19"},"enrollment":2589,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Thromboembolism"],"interventions":[{"type":"DRUG","name":"Warfarin","otherNames":[]},{"type":"DRUG","name":"Dabigatran etexilate","otherNames":[]}],"arms":[{"label":"Dabigatran etexilate (150mg bid)","type":"EXPERIMENTAL"},{"label":"Warfarin (INR 2.0-3.0)","type":"ACTIVE_COMPARATOR"}],"summary":"The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin Pro re nata (As needed/PRN) to maintain an International Normalised Ratio (INR) of 2.0-3.0 for 6 month treatment of acute symptomatic VTE.\n\nThe primary objective is to investigate the efficacy of dabigatran compared to warfarin during the 6 month treatment period. The investigation of other selected efficacy aspects and safety are regarded as secondary objective of this trial.","primaryOutcome":{"measure":"Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE","timeFrame":"For statistical analysis 1: from randomisation to end of post treatment period (ptp), planned to be up to day 224. For statistical analysis 2: from randomisation to 6 months (up to day 180)","effectByArm":[{"arm":"Dabigatran 150 mg","deltaMin":30,"sd":null},{"arm":"Warfarin","deltaMin":28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0002"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":220,"countries":["United States","Australia","Brazil","Bulgaria","Canada","China","Czechia","Denmark","France","Hungary","India","Israel","Italy","Malaysia","Netherlands","New Zealand","Norway","Philippines","Poland","Russia","Singapore","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["27807306","24344086","24081972"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":156,"n":1280},"commonTop":["Pain in extremity","Headache"]}}